辉瑞与三生制药就创新癌症治疗达成协议Pfizer Enters into Agreement with 3SBio for Innovative Cancer Treatment

动脉网
25 Jul

Pfizer has completed a global licensing agreement with 3SBio, excluding China, to develop, manufacture, and commercialise SSGJ-707 – a bispecific antibody targeting PD-1 and VEGF.辉瑞已完成与三生制药(3SBio)的全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10